Publication:
Reply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients".

Loading...
Thumbnail Image

Date

2021-04-03

Authors

Rodriguez-Peralvarez, Manuel
Colmenero, Jordi
Salcedo, Magdalena

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

We read with great interest the letter by G. J. Webb et al. regarding our recent nationwide study promoted by the Spanish Society of Liver Transplantation (SETH), which evaluated the incidence and outcomes of coronavirus disease 2019 (COVID-19) in liver transplant (LT) patients.2 The authors merged the SETH data with their own international cohort (COVID-Hep/SECURE-Cirrhosis)3 resulting in 258 LT patients with COVID-19. The combined data analysis allowed them to highlight the importance of age and comorbidities as key factors influencing outcomes. We completely agree with this conclusion, which may also be true for non-transplant patients with COVID19. However, some statements require further clarification.

Description

MeSH Terms

COVID-19
Calcineurin inhibitors
Comorbidity
Humans
Immunosuppressive agents
Liver transplantation
SARS-CoV-2

DeCS Terms

Comorbilidad
Inhibidores de la calcineurina
Inmunosupresores
Trasplante de hígado

CIE Terms

Keywords

COVID-19, SARS-CoV-2, Calcineurin inhibitors, Everolimus, Immunosuppression, Mycophenolate, Pneumonia, Tacrolimus, Transplantation

Citation

Rodríguez-Perálvarez M, Colmenero J, Salcedo M; Spanish Society of Liver Transplantation (SETH). Reply to: "Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients". J Hepatol. 2021 Jul;75(1):228-229